C

Caladrius Biosciences Inc
LSE:0HS8

Watchlist Manager
Caladrius Biosciences Inc
LSE:0HS8
Watchlist
Price: 2.58 USD -5.15%
Market Cap: 50m USD
Have any thoughts about
Caladrius Biosciences Inc?
Write Note

Caladrius Biosciences Inc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Caladrius Biosciences Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
C
Caladrius Biosciences Inc
LSE:0HS8
EPS (Diluted)
-$2
CAGR 3-Years
27%
CAGR 5-Years
37%
CAGR 10-Years
37%
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$2
CAGR 3-Years
-12%
CAGR 5-Years
6%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$0
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$7
CAGR 3-Years
-7%
CAGR 5-Years
-10%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
-$1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$40
CAGR 3-Years
-13%
CAGR 5-Years
16%
CAGR 10-Years
30%
No Stocks Found

Caladrius Biosciences Inc
Glance View

Market Cap
50m USD
Industry
Biotechnology

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.

0HS8 Intrinsic Value
1.86 USD
Overvaluation 28%
Intrinsic Value
Price
C

See Also

What is Caladrius Biosciences Inc's EPS (Diluted)?
EPS (Diluted)
-2.5 USD

Based on the financial report for Sep 30, 2024, Caladrius Biosciences Inc's EPS (Diluted) amounts to -2.5 USD.

What is Caladrius Biosciences Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
37%

Over the last year, the EPS (Diluted) growth was 5%. The average annual EPS (Diluted) growth rates for Caladrius Biosciences Inc have been 27% over the past three years , 37% over the past five years , and 37% over the past ten years .

Back to Top